LAVA Therapeutics N.V. articles
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity
- CD1d can be expressed by several hematologic malignancies
- Bispecific Vγ9Vδ2-T cell engager
- Unique ab
Roeland Lameris;Roeland Lameris;Jurjen M Ruben1;Iris de Weerdt;Rob Roovers;Arnon P Kater;Thilo Riedl;Victoria Iglesias;Benjamin Winograd;Ton EP Adang
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic potential, largely because of theircapacity to be triggered by phosphoantigens that can
Iris de Weerdt;Roeland Lameris1;Jurjen M. Ruben;Renate de Boer;Jan Kloosterman;Lisa A. King;Mark- David Levin;Paul W.H.I. Parren;Tanja D. de Gruijl;Arnon P. Kater;Hans J. van der Vliet